Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOASIS neoadjuvant pan-tumor basket study of botensilimab + balstilimab
2023-505756-21-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botensilimab and balstilimab in Nonhematologic neoplasms, colorectal cancer (CRC), esophageal cancer and 15 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Major pathologic response rate and Complete or near-complete response in dMMR rectal cancer organ preservation cohort. Planned start Jan 2024; status: authorised.
02
Drugs
botensilimabbalstilimab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)esophageal canceresophagogastric junction cancergastric cancer (GC)
Beyond the preview
Go deeper on 2023-505756-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505756-21-00.